Melanoma-specific antigen-associated antitumor antibody reactivity as an immune-related biomarker for targeted...

Area of Science:

• Oncology
• Immunology
• Biomarker Discovery

Background:

• Immunotherapies like cancer vaccines and immune checkpoint inhibitors have revolutionized cancer care.
• However, many patients exhibit resistance to these treatments, highlighting a need for predictive biomarkers.
• Current research offers limited insights into predicting responses to precision immunotherapy.

Purpose of the Study:

• To profile antibody responses and understand humoral immunity's role in targeted cancer therapies.
• To investigate the utility of antibody epitopes as predictive biomarkers for immunotherapy response.
• To compare immunogenicity across different targeted immune treatments.

Main Methods:

• Utilized next-generation phage display mimotope variation analysis (MVA).
• Analyzed antibody responses to anti-tumor dendritic cell vaccine (MelCancerVac®) and anti-PD-1 therapy (pembrolizumab).
• Characterized antibody epitopes linked to melanoma-associated antigens and cancer-testis antigens (CTA).

Main Results:

• Identified epitopes associated with antibody responses induced by MelCancerVac® in lung cancer.
• Found that several identified epitopes correlated with strong immune responses in melanoma patients receiving anti-PD-1 therapy.
• Demonstrated similarities and differences in tumor-specific immunogenicity between the two treatments.

Conclusions:

• Antibody epitopes can serve as biomarkers for melanoma-associated immune responses.
• These epitopes provide insights into cancer pathogenesis and molecular pathways.
• Antibody epitope response shows potential for predicting immunotherapy-induced anti-cancer immunity.